News
ARQT
27.60
-0.25%
-0.07
Arcutis gets FDA review for Zoryve 0.05% label expansion
Seeking Alpha · 1h ago
Arcutis' ZORYVE Crème SNDA Accepted By FDA For Infants With Atopic Dermatitis
NASDAQ · 3h ago
Arcutis Biotherapeutics's SNDA For ZORYVE Cream 0.05% Gets FD Acceptance
NASDAQ · 4h ago
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants
Dow Jones · 4h ago
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
TipRanks · 4h ago
FDA accepts Arcutis sNDA for Zoryve cream use in infants with atopic dermatitis
PUBT · 4h ago
FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%
Benzinga · 4h ago
ARCUTIS BIOTHERAPEUTICS - FDA SETS PDUFA TARGET ACTION DATE OF FEBRUARY 23, 2027 FOR ZORYVE CREAM 0.05% SNDA
Reuters · 4h ago
Weekly Report: what happened at ARQT last week (0629-0703)?
Weekly Report · 2d ago
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
The Motley Fool · 5d ago
Arcutis grants 61,000 RSUs to nine new hires under 2022 inducement plan
PUBT · 5d ago
ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Should ZORYVE’s New Pediatric Label and Virtual Platform Expansion Require Action From Arcutis (ARQT) Investors?
Simply Wall St · 06/30 22:14
Arcutis Buy Rating Reaffirmed as Zoryve Pediatric Label Expansion Supports Long-Term Growth; Price Target Maintained at $36
TipRanks · 06/30 15:55
ARCUTIS BIOTHERAPEUTICS - LAUNCHES VIRTUAL HEALTH PLATFORM TO EXPAND ACCESS TO ZORYVE PORTFOLIO
Reuters · 06/30 13:16
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Barchart · 06/30 08:15
Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children
Benzinga · 06/30 07:56
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
TipRanks · 06/29 23:30
Arcutis Biotherapeutics' Psoriasis Cream Gets FDA Approval for Young Children
Dow Jones · 06/29 23:15
Arcutis says FDA approves Zoryve cream for plaque psoriasis in children as young as 2
PUBT · 06/29 23:06
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.